Apo Allopurinol

Quick links

Choose a section

Quick links to important sections

Advertisements

Apo Allopurinol

Advertisements
Advertisements

Overview of Apo Allopurinol

Property Description
Active ingredient Allopurinol
Form Oral Tablets
Pharmacological class Xanthine Oxidase Inhibitor (Anti-uricaemic agent)
General purpose To reduce high blood uric acid levels (hyperuricaemia)
Origin Synthetic Purine Analogue

What Type of Medicine is Apo Allopurinol?

Apo Allopurinol is a prescription-only synthetic medication whose active ingredient is allopurinol, a chemical entity clinically recognized for its role in managing hyperuricaemia. It is classified as an anti-uricaemic agent and, more specifically, a powerful xanthine oxidase inhibitor.

The drug belongs to a specialized class of compounds designed to address chronic metabolic conditions, such as those that lead to the accumulation of uric acid. The allopurinol molecule is a synthetic purine analogue chemically manufactured to mimic natural compounds in the body, allowing it to specifically interfere with the purine catabolism pathway. The medication is used for maintaining balanced uric acid levels over time.


Composition and Preparation Form

The medication is a single-ingredient product, with allopurinol as the sole chemical entity, administered systemically in the common dosage form of an oral tablet. This form is preferred for treating chronic systemic conditions where long-term metabolic control is necessary. Allopurinol is structurally related to hypoxanthine, a natural purine compound, which enables its effective interaction with the target enzyme.

Following oral intake, allopurinol is converted within the body into its active metabolite, oxipurinol (alloxanthine), which contributes significantly to the sustained inhibition process. Allopurinol’s recognized role as an inhibitor of xanthine oxidase is crucial because this enzyme is directly responsible for generating uric acid.


What is the General Purpose of an Anti-Uricaemic Agent?

The general purpose of this medication is to achieve and maintain low, stable levels of uric acid in the bloodstream, thereby addressing hyperuricaemia. A typical use scenario involves preventing the escalation of uric acid levels in individuals where the body naturally overproduces this compound.

The drug's benefit stems directly from its ability to limit the accumulation of this metabolic end-product. By acting as a potent inhibitor of the xanthine oxidase enzyme, Apo Allopurinol ensures that the metabolic process of purine breakdown produces less total uric acid, fulfilling its primary objective of managing the chronic chemical imbalance.

Regulatory References

  1. NIH/NLM Drug Information
Advertisements

What side effects are possible with Apo Allopurinol?

Possible Side Effects and Safety Information

The safety profile of Apo Allopurinol is defined by official regulatory documentation that classifies adverse reactions by their frequency and the physiological system affected. The most frequently documented side effect is skin rash, which is officially categorized as common in labeling, alongside increases in blood thyroid stimulating hormone (TSH). Gastrointestinal upsets, such as nausea and vomiting, are typically classified as uncommon events.


Systemic Safety Classifications

Adverse effects are grouped into System-Organ Classes (SOCs) in regulatory data, including Skin and Subcutaneous Tissue Disorders, Hepatobiliary Disorders (e.g., abnormal liver function tests), and Blood and Lymphatic System Disorders (e.g., myelosuppression).

Serious Adverse Reactions

The most serious, though rare or very rare, reactions officially documented include Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Other serious events include severe suppression of blood cell production, such as agranulocytosis or aplastic anaemia. Regulatory labeling mandates the immediate discontinuation of the medicine upon the first appearance of a skin rash or other signs of hypersensitivity.


Population and Time-Related Safety

Official safety notes specify that patients with renal impairment require particular attention, as the drug and its metabolite are primarily cleared by the kidney. There are also specific safety considerations for individuals carrying the *HLA-B58:01 allele, who have an increased risk for severe skin reactions. Regarding timing, the regulatory data notes that acute gout flares may potentially occur during the initiation of treatment**.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for allopurinol overdose details specific documented manifestations and mandated emergency actions. Upon suspected or confirmed over-ingestion, the regulatory instruction is to seek immediate medical attention and contact a poison control center.

Overdose Profile Focus Documented Regulatory Information
Clinical Manifestations Overdose may present with common signs including nausea, vomiting, diarrhea, and dizziness. Severe physiological findings cited include oliguria (diminished urine output) and azotaemia (elevated nitrogen compounds in the blood).
Severe Outcomes The critical, life-threatening outcome cited is severe renal impairment or acute kidney failure, with risk of irreversible toxicity following massive cumulative overdosage.

Management and Monitoring Requirements

There is no specific antidote known for allopurinol overdose; therefore, management is based on symptomatic and supportive treatment. Procedural options documented include gastric lavage for recent ingestion and haemodialysis, which is cited as effective for removing the drug and its metabolite. Extended hospital observation is required, including mandatory monitoring of renal function and liver function. Furthermore, overdose effects may be more serious in elderly patients, and pre-existing renal impairment increases the risk of severe toxicity.

Advertisements

Therapeutic Uses of Apo Allopurinol

Understanding the Uses of Apo Allopurinol

Apo Allopurinol is a medication primarily prescribed to manage conditions associated with elevated levels of uric acid in the body. It belongs to a class of drugs known as xanthine oxidase inhibitors, which work by reducing the production of uric acid.

Management of Gout

The most common use for Apo Allopurinol is the long-term management of gout. Gout is a form of inflammatory arthritis characterized by the accumulation of uric acid crystals in the joints. When uric acid levels in the blood become too high, crystals can form, leading to sudden and severe attacks of pain, swelling, and redness.

By lowering the concentration of uric acid, Apo Allopurinol helps to:

  • Reduce the frequency of gout attacks.
  • Prevent the formation of new uric acid crystals.
  • Facilitate the gradual dissolution of existing crystal deposits (tophi) in the joints and soft tissues.

Prevention of Kidney Stones

Apo Allopurinol is also utilized to prevent the recurrence of certain types of kidney stones. Specifically, it is used for patients who form calcium oxalate stones due to high levels of uric acid in their urine, or for those who develop uric acid stones. By decreasing the amount of uric acid excreted by the kidneys, the medication reduces the likelihood of these stones crystallizing in the urinary tract.

Hyperuricemia Related to Medical Treatments

In certain medical scenarios, such as the treatment of some types of cancer, large numbers of cells are broken down rapidly. This process can release significant amounts of purines into the bloodstream, which are then converted into uric acid. Apo Allopurinol may be used in these instances to manage and prevent high uric acid levels, protecting the kidneys from potential damage caused by excessive crystal formation.

Long-Term Benefits

The primary benefit of Apo Allopurinol is its ability to maintain stable, lower levels of uric acid over time. Unlike medications used to treat acute pain, this medication is a preventive measure. Consistent use can lead to the long-term reduction of joint damage and the preservation of kidney function in individuals prone to high uric acid production.

Regulatory References

  1. Allopurinol: MedlinePlus Drug Information
Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Apo Allopurinol — Official Regulatory Information

Apo Allopurinol is an anti-uricaemic agent with use strictly defined by governmental labeling, focusing on specific population exclusions and conditional requirements.

Populations for whom use is contraindicated:

  • Patients with a known history of hypersensitivity or previous severe allergic reaction to allopurinol.
  • Women who are breastfeeding.
  • Patients currently experiencing an acute attack of gout.

Age-Related and Reproductive Eligibility:

  • Pediatric use is rarely indicated and not established for most conditions, restricted primarily to hyperuricemia secondary to malignancy or Lesch-Nyhan Syndrome.
  • Use during pregnancy is not recommended unless the prescribing physician determines it is absolutely required and the benefit outweighs the potential risk.

Condition-Specific Eligibility Restrictions:

  • Renal or Hepatic Impairment: Use requires reduced doses and caution, as the drug and its metabolite accumulate in these conditions.
  • Genetic Risk: The medicine is not recommended for patients who test positive for the *HLA-B58:01 allele** (common in Han Chinese, Thai, and Korean descent) unless clear benefits outweigh the higher risk of severe reactions.
  • Asymptomatic Hyperuricemia is not an indication for the use of allopurinol.

Official regulatory documents define eligibility based on absolute prohibitions for safety (e.g., prior hypersensitivity), conditional use tied to organ function or genetic markers, and established limits for age and reproductive status. This structure classifies specific groups as excluded, permitted under caution, or only eligible for specific, documented conditions.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Apo Allopurinol (allopurinol) is defined by its inhibitory effect on the xanthine oxidase enzyme and several other documented pharmacokinetic and pharmacodynamic interactions.

Formal Regulatory Restrictions

Co-administration with Pegloticase is formally prohibited by regulatory authorities as allopurinol interferes with the required monitoring of serum uric acid levels. Furthermore, regulatory agencies advise avoiding concomitant use with Capecitabine.

Clinically Significant Metabolic and Exposure Interactions

Allopurinol severely increases the plasma concentrations of Mercaptopurine and Azathioprine by inhibiting their metabolic clearance. This interaction necessitates a mandatory dose reduction of these co-administered drugs to one-third or one-quarter of the usual dose. Allopurinol may also enhance the anticoagulant effect of Warfarin, requiring frequent monitoring of the patient’s anticoagulation status.

Pharmacodynamic and Procedural Interactions

Concomitant use of allopurinol with Thiazide Diuretics increases the risk of severe hypersensitivity reactions, a risk that is explicitly stated as being higher in patients with decreased renal function. Separately, to ensure proper absorption, a 3-hour separation interval must be maintained between the administration of allopurinol and Aluminum Hydroxide antacids. Co-administration with certain antibiotics, such as Ampicillin or Amoxicillin, is associated with an increased incidence of skin rash.

Advertisements

Mechanism of Action

Inhibition of the Xanthine Oxidoreductase Enzyme

The core action of Apo Allopurinol centers on the inhibition of the enzyme Xanthine Oxidoreductase (XOR). The parent drug, allopurinol, and the active metabolite, oxipurinol, competitively bind to this enzyme, thereby blocking the final two enzymatic steps of purine catabolism. This mechanistic focus on enzyme blockade leads directly to the reduction of the body's overall production of uric acid.

Metabolic Pathway Rerouting and Feedback

By inhibiting XOR, the mechanism causes the intermediate purine bases, hypoxanthine and xanthine, to increase in concentration. This accumulation shifts these precursor compounds into the purine salvage pathway for re-utilization. This pathway modulation, alongside a resultant negative feedback signal, contributes to reducing the rate of de novo purine synthesis and maintaining a hypouricemic state.

Urate Concentration Dynamics

A physiological consequence of this enzyme inhibition is the sustained reduction of systemic uric acid concentration below its solubility threshold. By maintaining this low saturation state, the mechanism results in the dissolution of pre-existing urate crystals. Furthermore, the mechanism constrains the physical conditions required for new crystals to form.

Advertisements

Dosage and Administration Information

How to Use Apo Allopurinol: Official Administration Guidelines

Apo Allopurinol, containing the active ingredient allopurinol, is administered using a strict set of official protocols. The primary method of administration is oral via tablets for long-term chronic management. The intravenous (IV) infusion route is reserved for patients who cannot tolerate oral therapy or for specific clinical scenarios, such as preventing hyperuricemia during certain cancer treatments.


Official Dosing and Frequency

Therapy typically begins with a low initial daily oral dose, often 100 mg in adults. This dose is not static but is part of a gradual titration plan, where the daily amount is slowly increased, typically in increments of 100 mg weekly, until a stable maintenance level is achieved. The typical maintenance range spans from 200 mg to 800 mg daily.

For daily doses up to 300 mg, the medicine is usually taken once daily. However, for total daily doses greater than 300 mg, the medicine is officially used in divided doses to maintain consistency.


Administration Conditions and Adjustments

Oral tablets should be taken after meals to help minimize potential gastrointestinal discomfort. Patients are instructed to take the tablets with a full glass of water and maintain adequate fluid intake throughout the treatment period.

Crucially, a significant dose reduction is explicitly mandated for individuals with impaired kidney function. For example, official schedules call for a maximum of 100 mg daily for severe renal impairment. In pediatric cases related to oncology, administration is calculated based on the child's body surface area (100 mg/m^2) rather than a standard flat dose. Intravenous administration requires the drug to be diluted to a concentration no greater than 6 mg/mL before infusion.

Advertisements

Recent Clinical Evidence

Apo Allopurinol: Recent Clinical Evidence


Evidence for Chronic Gout and Persistent High Uric Acid Levels

The most extensive research for Apo Allopurinol has been studied for research exploring its use in individuals with chronic gout and high blood uric acid levels (hyperuricaemia). This research has primarily relied on Randomized Controlled Trials (RCTs) and systematic reviews. Studies examined the change in the serum uric acid (sUA) biomarker, and monitored the frequency of acute gout attacks (flares) and changes in tophi (crystalline deposits). Data show patterns related to reductions measured in the sUA biomarker. While core findings on sUA biomarker changes are broadly supported by research, long-term effects are not fully established across all secondary outcomes.


Evidence for Managing Uric Acid-Based Kidney Stones

Apo Allopurinol was evaluated in research exploring the recurrence of uric acid-based kidney stones. This relies on evidence including clinical documentation and research exploring outcomes related to physiological strain, tracking measurements of stone recurrence. Studies described patterns observed in the amount of uric acid excreted in the urine. Clinical documentation and observational data findings indicate patterns related to the long-term recurrence of kidney stones. Evidence is limited regarding recent, large-scale RCTs designed to track long-term stone recurrence.


Evidence for High Uric Acid During Malignant Conditions

Apo Allopurinol was observed in research contexts involving the risk of high uric acid levels that may occur during intensive cytotoxic therapy for specific malignant conditions. This research explored the potential for reducing the risk of a dangerous, acute complication called uric acid nephropathy. Clinical reports described patterns of rapid change measured in both serum and urinary urate biomarkers. A substantial body of evidence describes research on the risk of developing acute uric acid nephropathy during treatment.


Research Gaps and Uncertainty

Research encompasses both short-term trials and long-term observational settings. Long-term effects are not fully established for non-primary outcomes, and findings in these areas were mixed. Data for children are still emerging, with the exception of evidence for children with malignant diseases. Research does not determine whether an individual will respond similarly to the group patterns observed in studies, as findings describe group patterns, not personal outcomes.

Key Studies & References 2020 American College of Rheumatology Guideline for the Management of Gout

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Apo Allopurinol (FAQ)


Q: How quickly can I expect Apo Allopurinol to start working?

Official information indicates that a measurable drop in uric acid levels in the blood and urine is often observed within two to three days of starting the medicine. However, the full, stable effect needed for long-term management typically becomes apparent after a week or more of consistent treatment.


Q: Does Apo Allopurinol have a cumulative effect over time?

The medicine is converted in the body into an active substance called oxipurinol, which is cleared slowly. This slow clearance supports a sustained reduction of uric acid levels over time, which is the goal of chronic management. The effect generally reverses slowly, over several days, if treatment is stopped.


Q: Is Apo Allopurinol considered a long-term treatment?

Yes, regulatory documents describe this medication as being used for the long-term management of chronic conditions like hyperuricemia (high uric acid levels). Continued treatment is generally required indefinitely to maintain the uric acid levels within the target range.


Q: Do I need to change my diet while taking Apo Allopurinol?

While the medicine is the primary way to manage uric acid, official guidance often recommends complementary lifestyle and dietary modifications. These generally include maintaining a healthy body weight and limiting high-purine foods and alcohol for optimal condition management.


Q: Is it common to feel tired when starting Apo Allopurinol?

Yes, official side effect listings note that drowsiness and fatigue are among the possible effects that may occur when taking this medicine. Due to the potential for these effects, official warnings advise caution when performing activities that require alertness.


Q: Does Apo Allopurinol affect liver function?

Regulatory information notes that the medicine has the potential to cause hepatotoxicity (liver damage) and may lead to abnormal results in liver function tests. Monitoring liver enzymes may be necessary during the initial phases of therapy.


Q: Can Apo Allopurinol cause changes in mood or sleep?

The side effect profiles mention potential effects on the nervous system. These documented effects include symptoms such as drowsiness, anxiety, insomnia (sleeplessness), and depression.


Q: Are there any common over-the-counter medicines that interact with Apo Allopurinol?

The official documentation states that certain common over-the-counter products, specifically Aluminum Hydroxide antacids, require a time separation of three hours from allopurinol administration. Sources generally do not cite a formal interaction with common relievers like ibuprofen or paracetamol, and it is always important to consult with a healthcare professional regarding co-administration of any medications.


Q: What are the typical side effects that users report on forums?

According to regulatory sources, the most frequently documented side effects observed in clinical trials are skin rash, nausea, and diarrhea. If any potential adverse effects are experienced, regulatory guidance suggests informing a healthcare professional.


Q: What lifestyle changes are often recommended alongside Apo Allopurinol treatment?

Regulatory sources and clinical guidelines frequently mention several supporting lifestyle changes. These often include maintaining adequate fluid intake, achieving and sustaining a healthy body weight, and limiting consumption of alcohol and high-purine foods.


Q: If I feel better, can I just stop taking Apo Allopurinol?

Since the medicine is used for chronic control, official patient instructions emphasize that the medicine should not be stopped without guidance from the prescribing professional. Treatment is generally intended to be continued to maintain stable uric acid levels.


Q: Are there any known interactions between Apo Allopurinol and alcohol?

Regulatory-cited information advises that alcohol use be avoided or limited. Alcohol consumption can potentially increase the risk of nervous system side effects like drowsiness and dizziness, and it may also raise the risk of gout flares.


Q: Why is regular blood testing sometimes needed when taking this medication?

Regular blood tests are required to monitor the serum uric acid levels in the bloodstream. This monitoring ensures that the prescribed dose is effectively achieving and maintaining the specific therapeutic target concentration.


Q: Will I need to take Apo Allopurinol forever?

Following achievement of the target uric acid concentration, the medicine is generally required to continue indefinitely to maintain chronic control of hyperuricemia and prevent complications.


Q: Is Apo Allopurinol appropriate for people who have had organ transplants?

The medicine may be used in this population, but official warnings state that a mandatory dose reduction is required for co-administered immunosuppressants like Azathioprine and Mercaptopurine. This is due to a severe interaction that increases the concentration of the transplant medications.


Q: Are there different Apo Allopurinol tablet strengths available?

Yes, the active ingredient, allopurinol, is commonly available in oral tablet form. Regulatory-cited standard strengths typically include 100 mg and 300 mg tablets.


Q: Do any studies suggest Apo Allopurinol helps with high blood pressure?

Research, including some observational studies, has been conducted that explores a possible association between allopurinol use and lower rates of specific cardiovascular events. However, definitive prospective clinical trials are still needed to fully evaluate if there is a direct benefit for high blood pressure.


Q: Can taking Apo Allopurinol affect my ability to drive?

Official warnings state that this medicine may cause side effects such as dizziness, drowsiness, or a lack of coordination. Patients are advised to know how the medication affects them before driving or operating machinery.


Q: Can Apo Allopurinol cause hair loss?

Yes, hair loss (alopecia) is listed as a potential, though typically reversible, side effect in some authoritative side effect documentation.


Q: Does Apo Allopurinol interact with common pain relievers like ibuprofen?

Sources generally indicate no formal interaction between allopurinol and common non-prescription pain relievers like ibuprofen or paracetamol. Consulting with a healthcare professional is always recommended before combining any medications.


Q: What should I know about Apo Allopurinol if I have a history of heart problems?

Official labeling states that individuals with a history of conditions such as heart failure need to discuss this with their prescribing professional before starting this medication. Research has also explored the medicine's association with various cardiovascular outcomes.


Q: How do I know if the Apo Allopurinol is actually working?

The effectiveness of the treatment is confirmed through regular blood tests. These tests show whether the serum uric acid level in the bloodstream is consistently maintained at the desired therapeutic concentration, usually less than 6 mg/dL.


Q: Does the effectiveness of Apo Allopurinol depend on my ethnic background?

While effectiveness is not linked to ethnic background, official-cited information notes that individuals of Han-Chinese, Korean, or Thai descent have a higher documented risk of severe skin reactions. This is due to a genetic marker called the *HLA-B58:01 allele**.


Q: Can Apo Allopurinol be used to manage high uric acid from certain medications?

The medicine is officially indicated for the management and prevention of elevated uric acid levels that occur due to specific treatments. This includes high uric acid levels resulting from certain chemotherapy medications.


Q: Is a low purine diet still necessary when taking Apo Allopurinol?

The medication is the primary control method, but lifestyle support, including limiting foods high in purines, alcohol, and high-fructose corn syrup, is generally recommended. These measures are often seen as complementary steps for managing the underlying condition.


Q: How long does it take for uric acid levels to potentially drop after starting?

A decrease in both serum and urinary uric acid levels is generally observed within two to three days after the initiation of therapy, according to clinical pharmacology data.


Q: Does Apo Allopurinol carry a risk of vision changes?

Some authoritative side effect listings include vision impairment or eye irritation as a potential risk associated with the use of this medicine.

Advertisements

How should Apo Allopurinol be stored and disposed of?

How to Store and Dispose of Apo Allopurinol?

Storage Conditions

Apo-Allopurinol tablets must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The medication should be stored in the original container with the cap tightly closed and protected from light and moisture. It is required to keep the tablets out of the reach and sight of children.


Disposal Instructions

Unused or expired Apo-Allopurinol must not be disposed of in household waste or wastewater (flushed down the toilet or sink). Disposal must comply with local regulations, typically requiring the medicine to be returned to a pharmacist or collected via an official drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Apo Allopurinol found in:

A-Z Index: